Skip to content
Peptide for Paws Animals, movement, published research

The veterinary reading list

The paw-pad paper is the oldest curiosity here. The walking and feline diabetes trials take the story into quite different animals and outcomes.

Dog studies

Start with Swaim and colleagues’ dog paw-pad wound study and Dobenecker and colleagues’ oral collagen study in dogs with osteoarthritis. I value the distance between their questions: tissue in an experimental wound on one side, movement in dogs with naturally occurring disease on the other.

The BPC-157 preclinical safety paper and rat-and-beagle pharmacokinetic paper describe laboratory work. The TB-500 paper in horses develops a doping-control method. None supplies a treatment result for a pet dog with arthritis.

Cat diabetes studies

The newly diagnosed cat trial and the remission-maintenance trial are the central pair. The placebo-controlled study in obese client-owned cats supplies additional adverse-effect context. I’d read the population and outcome before deciding how to connect the papers.

Animal-drug guidance

The animal-drug approval process, label-status guide, animal-drug questions, extra-label regulations and side-effect reporting guide explain the veterinary setting around the research. The FDA’s concerns about unapproved animal drugs include the missing reporting obligation that makes a quiet record hard to interpret.

Approval and search statements on this site are tied to checks dated September 30, 2026. These records are snapshots; later changes require a fresh check. The animal-drug database and minor-species Index are separate records.

  1. Animal Drugs @ FDA (searchable database of approved and conditionally approved animal drugs) ↗
  2. How Can I Tell If a Drug Is Legally Marketed for Animals? ↗
  3. FDA's Concerns about Unapproved Animal Drugs ↗
  4. Frequently Asked Questions about Animal Drugs ↗
  5. From an Idea to the Marketplace: The Journey of an Animal Drug through the Approval Process ↗
  6. 21 CFR Part 530, Extralabel Drug Use in Animals (sections 530.2, 530.3, 530.13, 530.20, 530.30) ↗
  7. How to Report Animal Drug and Device Side Effects and Product Problems ↗
  8. Index of Legally Marketed Unapproved New Animal Drugs for Minor Species ↗
  9. Gilor C, et al. Assessment of exenatide extended-release for maintenance of diabetic remission in cats. J Vet Intern Med 2025;39:e70069. ↗
  10. Riederer A, et al. Effect of the GLP-1 analogue exenatide extended release in cats with newly diagnosed diabetes mellitus. J Vet Intern Med 2016;30:92-100. ↗
  11. Hoelmkjaer KM, et al. A placebo-controlled study on the effects of exenatide ... in obese, client-owned cats. PLoS One 2016;11:e0154727. ↗
  12. Xu C, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol 2020;114:104665. ↗
  13. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 ... in rats and dogs. Front Pharmacol 2022;13:1026182. ↗
  14. Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma. J Chromatogr A 2012;1265:57-69. ↗
  15. Swaim SF, et al. Effect of locally injected medications on healing of pad wounds in dogs. Am J Vet Res 1996;57:394-9. ↗
  16. Dobenecker B, et al. The oral intake of specific bioactive collagen peptides improves gait and quality of life in canine osteoarthritis patients. PLoS One 2024;19:e0308378. ↗